

REGENERON PHARMACEUTICALS INC
Form DEFA14A
April 28, 2011

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- | | |
|--|---|
| <input type="checkbox"/> Preliminary Proxy Statement | <input type="checkbox"/> Soliciting Material Under Rule |
| <input type="checkbox"/> Confidential, For Use of the
Commission Only (as permitted
by Rule 14a-6(e)(2)) | 14a-12 |
| <input type="checkbox"/> Definitive Proxy Statement | |
| <input checked="" type="checkbox"/> Definitive Additional Materials | |

Regeneron Pharmaceuticals, Inc

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
 Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

Fee paid previously with preliminary materials:

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

1) Amount previously paid:

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form DEFA14A

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:

***** Exercise Your Right to Vote *****

Important Notice Regarding the Availability of Proxy Materials for the
Shareholder Meeting to Be Held on June 10, 2011

REGENERON PHARMACEUTICALS, INC.

REGENERON PHARMACEUTICALS, INC.
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591-6707

Meeting Information

Meeting Type: Annual Meeting

For holders as of: April 13, 2011

Date: June 10, 2011 Time: 10:30 AM EDT

Location: Westchester Marriott Hotel
670 White Plains Road
Tarrytown, New York 10591
For Meeting Directions go to:
www.regeneron.com

You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form DEFA14A

Voting items

The Board of Directors recommends you vote FOR the following:

1. Election of Directors
Nominees
01 Alfred G Gilman MD02 Joseph L. Goldstein M.D 03 Christine A. Poon 04 P. Roy Vagelos,
Ph.D M.D.

The Board of Directors recommends you vote FOR proposals 2, 3 and 4.

2. Proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2011.
3. Proposal to approve the Company's Second Amended and Restated 2000 Long-Term Incentive Plan.
4. Proposal to approve, by non-binding advisory vote, executive compensation.

The Board of Directors recommends you vote 3 YEARS on the following proposal:

5. Proposal to recommend, by non-binding advisory vote, the frequency of future advisory votes on executive compensation.

NOTE: In their discretion, the named proxies may vote on such other business as may properly come before the Annual Meeting or at any adjourned or postponed session thereof.

